Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Lixte Biotech Hlds (LIXT)

$6.01 +0.74 (13.95%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	27.39M
Revenue (ttm)	0.00
Net Income (ttm)	-3.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	330,100
Avg Vol	1,618,110
Day's Range	N/A - N/A
Shares Out	4.56M
Stochastic %K	89%
Beta	0.46
Analysts	Strong Buy
Price Target	N/A

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab t...

Industry: Biotechnology

Sector: Healthcare

Phone: 631 830 7092

Fax: 631 982 5050

Website: lixte.com

Address:

680 East Colorado Boulevard, Suite 180, Pasadena, United States

Orlandotrader Sep. 13 at 3:57 PM

$LIXT Great Week!!!! RSI off the Charts for the Daily and Weekly. Normally I would be selling but have only 1000 shares. Will add on Dips back to 5$ if it’s even possible. Momentum is hard to Fade. And to think I had 10,000 shares at 1.11.😂

1 · Reply

JD101 Sep. 13 at 12:28 AM

$LIXT next $SONN

0 · Reply

JD101 Sep. 12 at 9:51 PM

$LIXT $GNLX $VVOS $PBM

0 · Reply

theshortsqueezer2022 Sep. 12 at 5:00 PM

$LIXT 💰🤑

0 · Reply

JD101 Sep. 12 at 3:06 PM

$LIXT massive downside trend break … pick you upside target … $20 … $40 this can blast

0 · Reply

Scoty_D Sep. 12 at 2:50 PM

$LIXT

0 · Reply

JD101 Sep. 12 at 2:33 PM

$LIXT beast

0 · Reply

J_Russ4Life Sep. 11 at 6:34 PM

$LIXT NXXT relative strength versus peers stands out. Uptrend intact while sector chops. That divergence usually resolves with another leg.

0 · Reply

RichMitch2025 Sep. 11 at 6:24 PM

$LIXT NXXT storage plus solar combo plays into grid resilience narrative. Policy tailwinds remain strong. Expect premium multiples as deployments accelerate.

0 · Reply

DylanGFM Sep. 11 at 6:07 PM

$ASYS and $LIXT both good swings

0 · Reply

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

Sep 5, 2025, 8:35 AM EDT - 9 days ago

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

Sep 3, 2025, 8:00 AM EDT - 11 days ago

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Aug 27, 2025, 8:15 AM EDT - 18 days ago

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

Aug 25, 2025, 8:05 AM EDT - 20 days ago

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Aug 19, 2025, 11:18 AM EDT - 26 days ago

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

Aug 18, 2025, 8:00 AM EDT - 27 days ago

LIXTE Biotechnology Holdings Provides Corporate Update

Aug 14, 2025, 9:06 PM EDT - 4 weeks ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Aug 14, 2025, 8:05 AM EDT - 4 weeks ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

Aug 13, 2025, 8:49 AM EDT - 4 weeks ago

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

Aug 13, 2025, 7:30 AM EDT - 4 weeks ago

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

Jul 16, 2025, 8:05 AM EDT - 2 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Jul 9, 2025, 5:15 PM EDT - 2 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Jul 9, 2025, 8:05 AM EDT - 2 months ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 8, 2025, 2:57 PM EDT - 2 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 2, 2025, 4:05 PM EDT - 2 months ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 2 months ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Mar 31, 2025, 8:30 AM EDT - 5 months ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 27, 2025, 8:30 AM EDT - 6 months ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Feb 25, 2025, 8:30 AM EST - 7 months ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 13, 2025, 10:35 AM EST - 7 months ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 7 months ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 10, 2025, 5:00 PM EST - 7 months ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Sep 4, 2024, 8:30 AM EDT - 1 year ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Aug 26, 2024, 8:30 AM EDT - 1 year ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 19, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 15, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 14, 2024, 10:50 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Jun 14, 2024, 11:00 AM EDT - 1 year ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 6, 2024, 8:30 AM EDT - 1 year ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 3, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

May 20, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 8, 2024, 9:25 AM EDT - 1 year ago

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Mar 21, 2024, 8:30 AM EDT - 1 year ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Feb 27, 2024, 8:30 AM EST - 1 year ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Feb 26, 2024, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Jan 29, 2024, 8:30 AM EST - 1 year ago

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

Nov 13, 2023, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Oct 9, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Sep 26, 2023, 8:30 AM EDT - 2 years ago

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Sep 20, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Jul 20, 2023, 4:05 PM EDT - 2 years ago

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Jun 23, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Jun 7, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

Jun 2, 2023, 12:30 PM EDT - 2 years ago

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

May 30, 2023, 8:30 AM EDT - 2 years ago

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology's Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

Apr 24, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Apr 4, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope's Ongoing Phase 1b Clinical Trial in Evaluating Lixte's Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

Feb 14, 2023, 1:50 PM EST - 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

Orlandotrader Sep. 13 at 3:57 PM

1 · Reply

JD101 Sep. 13 at 12:28 AM

$LIXT next $SONN

0 · Reply

JD101 Sep. 12 at 9:51 PM

$LIXT $GNLX $VVOS $PBM

0 · Reply

theshortsqueezer2022 Sep. 12 at 5:00 PM

$LIXT 💰🤑

0 · Reply

JD101 Sep. 12 at 3:06 PM

$LIXT massive downside trend break … pick you upside target … $20 … $40 this can blast

0 · Reply

Scoty_D Sep. 12 at 2:50 PM

$LIXT

0 · Reply

JD101 Sep. 12 at 2:33 PM

$LIXT beast

0 · Reply

J_Russ4Life Sep. 11 at 6:34 PM

$LIXT NXXT relative strength versus peers stands out. Uptrend intact while sector chops. That divergence usually resolves with another leg.

0 · Reply

RichMitch2025 Sep. 11 at 6:24 PM

$LIXT NXXT storage plus solar combo plays into grid resilience narrative. Policy tailwinds remain strong. Expect premium multiples as deployments accelerate.

0 · Reply

DylanGFM Sep. 11 at 6:07 PM

$ASYS and $LIXT both good swings

0 · Reply

DylanGFM Sep. 11 at 5:56 PM

$LIXT beautiful swing up from under a dollar they got a nice 5x from beginning of July with some good day trades too!

0 · Reply

DylanGFM Sep. 11 at 5:54 PM

$VNCE $OPAD both $LIXT and $ASYS might be setting up but $ASYS just got the comment from Zacks research certified stock tweets dude on the stock itself

0 · Reply

DylanGFM Sep. 11 at 5:47 PM

$BSGM $TGL $VNCE $WLDS ok we got another $LIXT it's a biotech low volume not even over 10% yet but with crypto catalyst And RV over 5... If vol continues to increase and it sets up it could have a good power hour run but not too sure.

0 · Reply